ClinicalTrials.gg

TargetBeta

TGFB1

transforming growth factor beta 1 · also CED, TGFbeta, TGFB, DPD1 · Transforming growth factor beta family

7 programs in company-led studies act on TGFB1, from 7 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
retlirafusp alfaruleJiangsu HengRui Medicinephase 3206 runningCD274NCIt
Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890ruleIncytephase 333 runningPDCD1NCIt
ficerafusp alfaruleBicara Therapeuticsphase 333 runningEGFRNCIt
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 342 runningPDCD1the company's pipeline
Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18ruleSuzhou Zelgen Biopharmaceuticalsphase 222 runningVEGFANCIt
Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028ruleArsenal Biosciencesphase 210 runningFAS, FOLH1, TGFBR2NCIt
Anti-GARP Monoclonal Antibody PBA-0111rulePure Biologicsearly phase 111 runningLRRC32NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.